Omeros CorpNASDAQ:OMER
- LAST PRICE3.9550
- TODAY'S CHANGE (%)0.0350 (0.8929%)
- Bid / Lots3.9400/ 8
- Ask / Lots3.9600/ 2
- Open / Previous Close3.9100 / 3.9200
- Day Range
- 52 Week Range
- Volume147,124
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 5258 | 3.91 |
| 09:39 ET | 100 | 3.96 |
| 09:43 ET | 3400 | 3.975 |
| 09:45 ET | 1100 | 3.98 |
| 09:48 ET | 700 | 3.98 |
| 09:50 ET | 1500 | 3.96 |
| 09:52 ET | 200 | 3.9781 |
| 09:56 ET | 1916 | 3.93 |
| 09:59 ET | 100 | 3.95 |
| 10:01 ET | 100 | 3.945 |
| 10:03 ET | 3337 | 3.945 |
| 10:06 ET | 775 | 3.96 |
| 10:12 ET | 100 | 3.9794 |
| 10:14 ET | 760 | 3.98 |
| 10:15 ET | 3610 | 3.975 |
| 10:17 ET | 100 | 3.97 |
| 10:19 ET | 400 | 3.97 |
| 10:28 ET | 4400 | 3.945 |
| 10:30 ET | 1200 | 3.955 |
| 10:32 ET | 863 | 3.94 |
| 10:35 ET | 100 | 3.94 |
| 10:37 ET | 6930 | 3.94 |
| 10:39 ET | 2027 | 3.925 |
| 10:42 ET | 600 | 3.935 |
| 10:46 ET | 400 | 3.935 |
| 10:50 ET | 1000 | 3.93 |
| 10:53 ET | 1600 | 3.935 |
| 10:55 ET | 200 | 3.935 |
| 10:57 ET | 587 | 3.94 |
| 11:00 ET | 800 | 3.94 |
| 11:04 ET | 1400 | 3.94 |
| 11:06 ET | 452 | 3.94 |
| 11:08 ET | 300 | 3.94 |
| 11:09 ET | 2458 | 3.97 |
| 11:11 ET | 2300 | 3.965 |
| 11:15 ET | 1572 | 3.985 |
| 11:20 ET | 3000 | 3.99 |
| 11:22 ET | 300 | 3.98 |
| 11:24 ET | 300 | 3.985 |
| 11:26 ET | 1100 | 3.985 |
| 11:27 ET | 6205 | 3.98 |
| 11:29 ET | 200 | 3.98 |
| 11:31 ET | 200 | 3.98 |
| 11:33 ET | 200 | 3.955 |
| 11:38 ET | 300 | 3.95 |
| 11:40 ET | 262 | 3.935 |
| 11:42 ET | 200 | 3.94 |
| 11:44 ET | 100 | 3.93 |
| 11:45 ET | 745 | 3.925 |
| 11:47 ET | 1000 | 3.92 |
| 11:49 ET | 202 | 3.92 |
| 11:51 ET | 900 | 3.915 |
| 11:54 ET | 500 | 3.91 |
| 12:00 ET | 500 | 3.91 |
| 12:03 ET | 1208 | 3.91 |
| 12:05 ET | 400 | 3.91 |
| 12:07 ET | 262 | 3.905 |
| 12:09 ET | 400 | 3.9 |
| 12:12 ET | 600 | 3.9 |
| 12:14 ET | 2554 | 3.9 |
| 12:16 ET | 1700 | 3.9 |
| 12:20 ET | 100 | 3.9 |
| 12:23 ET | 467 | 3.9 |
| 12:25 ET | 800 | 3.9 |
| 12:32 ET | 26105 | 3.91 |
| 12:34 ET | 4884 | 3.87 |
| 12:36 ET | 300 | 3.89 |
| 12:39 ET | 600 | 3.88 |
| 12:41 ET | 100 | 3.895 |
| 12:43 ET | 11781 | 3.955 |
| 12:48 ET | 1187 | 3.9734 |
| 12:50 ET | 100 | 3.975 |
| 12:52 ET | 1700 | 3.97 |
| 12:56 ET | 110 | 3.978 |
| 12:59 ET | 300 | 3.9721 |
| 01:03 ET | 9103 | 3.95 |
| 01:14 ET | 100 | 3.955 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 228.3M | -1.2x | --- |
Compass Therapeutics Inc. | 227.0M | -5.0x | --- |
Zentalis Pharmaceuticals Inc | 230.1M | -1.3x | --- |
Pyxis Oncology Inc | 222.8M | -2.9x | --- |
Zura Bio Ltd | 236.0M | -8.1x | --- |
Immutep Ltd | 346.0M | -9.1x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance, Treasurer
- David Borges
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $228.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-3.32 |
Book Value | $-0.41 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
